the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, randomized, expanded/phase II study in subjects with metastatic
castrate resistant prostate cancer (mCRPC) who progressed after either abiraterone or
enzalutamide.
The objective of the study is to evaluate the safety and tolerability of proxalutamide and
determine the RP2D for Ph III and/or other confirming studies.
Subjects will be randomized into the 2 treatment arms.